MX2016011730A - Compuestos para erradicar o inhibir la proliferacion de las celulas madre de cancer. - Google Patents

Compuestos para erradicar o inhibir la proliferacion de las celulas madre de cancer.

Info

Publication number
MX2016011730A
MX2016011730A MX2016011730A MX2016011730A MX2016011730A MX 2016011730 A MX2016011730 A MX 2016011730A MX 2016011730 A MX2016011730 A MX 2016011730A MX 2016011730 A MX2016011730 A MX 2016011730A MX 2016011730 A MX2016011730 A MX 2016011730A
Authority
MX
Mexico
Prior art keywords
stem cells
cancer stem
compounds
eradicating
inhibiting proliferation
Prior art date
Application number
MX2016011730A
Other languages
English (en)
Spanish (es)
Inventor
Srivastava Sangeeta
Athavale Maithili
Shukre Kedar
More Gayatri
Original Assignee
Godavari Biorefineries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Godavari Biorefineries Ltd filed Critical Godavari Biorefineries Ltd
Publication of MX2016011730A publication Critical patent/MX2016011730A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016011730A 2014-03-11 2015-03-11 Compuestos para erradicar o inhibir la proliferacion de las celulas madre de cancer. MX2016011730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2015/050019 WO2015136556A2 (en) 2014-03-11 2015-03-11 Compounds for eradicating or inhibiting proliferation of cancer stem cells
IN814MU2014 IN2014MU00814A (enExample) 2014-03-11 2015-03-11

Publications (1)

Publication Number Publication Date
MX2016011730A true MX2016011730A (es) 2016-12-14

Family

ID=54072549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011730A MX2016011730A (es) 2014-03-11 2015-03-11 Compuestos para erradicar o inhibir la proliferacion de las celulas madre de cancer.

Country Status (9)

Country Link
US (1) US20170022215A1 (enExample)
EP (1) EP3116882A4 (enExample)
JP (1) JP2017507163A (enExample)
AU (1) AU2015228385A1 (enExample)
CA (1) CA2940807A1 (enExample)
IL (1) IL247720A0 (enExample)
IN (1) IN2014MU00814A (enExample)
MX (1) MX2016011730A (enExample)
WO (1) WO2015136556A2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD248593A1 (de) * 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
WO2005021552A1 (en) * 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation

Also Published As

Publication number Publication date
CA2940807A1 (en) 2015-09-17
US20170022215A1 (en) 2017-01-26
WO2015136556A2 (en) 2015-09-17
WO2015136556A3 (en) 2016-01-14
AU2015228385A1 (en) 2016-09-15
EP3116882A2 (en) 2017-01-18
JP2017507163A (ja) 2017-03-16
IL247720A0 (en) 2016-11-30
IN2014MU00814A (enExample) 2015-09-25
EP3116882A4 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EA201691916A1 (ru) Биарильные ингибиторы киназы
PH12015502028A1 (en) Ido inhibitors
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
TW201613966A (en) SynTac polypeptides and uses thereof
MX380250B (es) Compuestos farmacéuticos inhibidores de cinasa chk-1.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MX2021006326A (es) Inhibidores de pcna.
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201691896A1 (ru) Соединения и способы их применения